Related references
Note: Only part of the references are listed.PARP inhibitor BMN-673 induced apoptosis by trapping PARP-1 and inhibiting base excision repair via modulation of pol-β in chromatin of breast cancer cells
Chinmayee Sethy et al.
TOXICOLOGY AND APPLIED PHARMACOLOGY (2022)
Cancer Statistics, 2021
Rebecca L. Siegel et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
Veliparib in Combination With Platinum-Based Chemotherapy for First-Line Treatment of Advanced Squamous Cell Lung Cancer: A Randomized, Multicenter Phase III Study
Suresh S. Ramalingam et al.
JOURNAL OF CLINICAL ONCOLOGY (2021)
PARP inhibitor Veliparib (ABT-888) enhances the anti-angiogenic potentiality of Curcumin through deregulation of NECTIN-4 in oral cancer: Role of nitric oxide (NO)
Subhajit Chatterjee et al.
CELLULAR SIGNALLING (2021)
Phase II trial of veliparib and temozolomide in metastatic breast cancer patients with and without BRCA1/2 mutations
Jing Xu et al.
BREAST CANCER RESEARCH AND TREATMENT (2021)
Olaparib enhances curcumin-mediated apoptosis in oral cancer cells by inducing PARP trapping through modulation of BER and chromatin assembly
Sefinew Molla et al.
DNA REPAIR (2021)
Clinical effectiveness of olaparib monotherapy in germline BRCA-mutated, HER2-negative metastatic breast cancer in a real-world setting: phase IIIb LUCY interim analysis
Karen A. Gelmon et al.
EUROPEAN JOURNAL OF CANCER (2021)
PARP1-modulated chromatin remodeling is a new target for cancer treatment
Saptarshi Sinha et al.
MEDICAL ONCOLOGY (2021)
Safety and efficacy of veliparib plus carboplatin/paclitaxel in patients with HER2-negative metastatic or locally advanced breast cancer: subgroup analyses by germline BRCA1/2 mutations and hormone receptor status from the phase-3 BROCADE3 trial
Jean-Pierre Ayoub et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2021)
PARP inhibitor Olaparib Enhances the Apoptotic Potentiality of Curcumin by Increasing the DNA Damage in Oral Cancer Cells through Inhibition of BER Cascade
Sefinew Molla et al.
PATHOLOGY & ONCOLOGY RESEARCH (2020)
Restoration of Temozolomide Sensitivity by PARP Inhibitors in Mismatch Repair Deficient Glioblastoma is Independent of Base Excision Repair
Fumi Higuchi et al.
CLINICAL CANCER RESEARCH (2020)
y Low-Dose and Long-Term Olaparib Treatment Sensitizes MDA-MB-231 and SUM1315 Triple-Negative Breast Cancers Spheroids to Fractioned Radiotherapy
Clemence Dubois et al.
JOURNAL OF CLINICAL MEDICINE (2020)
PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation
Ahrum Min et al.
CANCERS (2020)
Combination Therapy With Charged Particles and Molecular Targeting: A Promising Avenue to Overcome Radioresistance
Katrien Konings et al.
FRONTIERS IN ONCOLOGY (2020)
Tumor microenvironment complexity and therapeutic implications at a glance
Roghayyeh Baghba et al.
CELL COMMUNICATION AND SIGNALING (2020)
The Multifactorial Role of PARP-1 in Tumor Microenvironment
Juan Manuel Marti et al.
CANCERS (2020)
Nanoformulated quinacrine regulates NECTIN-4 domain specific functions in cervical cancer stem cells
Subhajit Chatterjee et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2020)
TBCRC 048: Phase II Study of Olaparib for Metastatic Breast Cancer and Mutations in Homologous Recombination-Related Genes
Nadine M. Tung et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Poly-ADP ribosylation in DNA damage response and cancer therapy
Wei-Hsien Hou et al.
MUTATION RESEARCH-REVIEWS IN MUTATION RESEARCH (2019)
N6-Methylation of Adenosine of FZD10 mRNA Contributes to PARP Inhibitor Resistance
Takeshi Fukumoto et al.
CANCER RESEARCH (2019)
Therapeutic considerations of PARP in stem cell biology: Relevance in cancer and beyond
M. Zeniou et al.
BIOCHEMICAL PHARMACOLOGY (2019)
Maintenance Olaparib for Germline BRCA-Mutated Metastatic Pancreatic Cancer
Talia Golan et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
PARP1 Trapping by PARP Inhibitors Drives Cytotoxicity in Both Cancer Cells and Healthy Bone Marrow
Todd A. Hopkins et al.
MOLECULAR CANCER RESEARCH (2019)
Replication Stress Drives Constitutive Activation of the DNA Damage Response and Radioresistance in Glioblastoma Stem-like Cells
Ross D. Carruthers et al.
CANCER RESEARCH (2018)
Anti-angiogenesis for cancer: Current status and prospects
Massimo Russo et al.
THROMBOSIS RESEARCH (2018)
Mechanisms of Oncogene-Induced Replication Stress: Jigsaw Falling into Place
Panagiotis Kotsantis et al.
CANCER DISCOVERY (2018)
Radiosensitization Effect of Talazoparib, a Parp Inhibitor, on Glioblastoma Stem Cells Exposed to Low and High Linear Energy Transfer Radiation
Paul Lesueur et al.
SCIENTIFIC REPORTS (2018)
Optimizing poly (ADP-ribose) polymerase inhibition through combined epigenetic and immunotherapy
Thiru Prasanna et al.
CANCER SCIENCE (2018)
Trabectedin and olaparib in patients with advanced and non-resectable bone and soft-tissue sarcomas (TOMAS): an open-label, phase 1b study from the Italian Sarcoma Group
Giovanni Grignani et al.
LANCET ONCOLOGY (2018)
Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation
Jennifer K. Litton et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Replication Stress: An Achilles' Heel of Glioma Cancer Stem-like Cells
Meredith A. Morgan et al.
CANCER RESEARCH (2018)
NAMPT Is a Potent Oncogene in Colon Cancer Progression that Modulates Cancer Stem Cell Properties and Resistance to Therapy through Sirt1 and PARP
Antonio Lucena-Cacace et al.
CLINICAL CANCER RESEARCH (2018)
Synthetic Lethality of PARP Inhibitors in Combination with MYC Blockade Is Independent of BRCA Status in Triple-Negative Breast Cancer
Jason. P. W. Carey et al.
CANCER RESEARCH (2018)
RAD51 Mediates Resistance of Cancer Stem Cells to PARP Inhibition in Triple-Negative Breast Cancer
Yajing Liu et al.
CLINICAL CANCER RESEARCH (2017)
Veliparib in combination with whole-brain radiation therapy for patients with brain metastases from non-small cell lung cancer: results of a randomized, global, placebo-controlled study
Pierre Chabot et al.
JOURNAL OF NEURO-ONCOLOGY (2017)
The impact of replication stress on replication dynamics and DNA damage in vertebrate cells
Herve Techer et al.
NATURE REVIEWS GENETICS (2017)
The multifaceted roles of PARP1 in DNA repair and chromatin remodelling
Arnab Ray Chaudhuri et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2017)
PARP inhibitors: Synthetic lethality in the clinic
Christopher J. Lord et al.
SCIENCE (2017)
Enhancing the Cytotoxic Effects of PARP Inhibitors with DNA Demethylating Agents - A Potential Therapy for Cancer
Nidal E. Muvarak et al.
CANCER CELL (2016)
ABT-888 and quinacrine induced apoptosis in metastatic breast cancer stem cells by inhibiting base excision repair via adenomatous polyposis coli
Sumit Siddharth et al.
DNA REPAIR (2016)
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
Yves Pommier et al.
SCIENCE TRANSLATIONAL MEDICINE (2016)
PARP-1 may be involved in angiogenesis in epithelial ovarian cancer
Wei Wei et al.
ONCOLOGY LETTERS (2016)
Randomized phase II study evaluating veliparib (ABT-888) with temozolomide in patients with metastatic melanoma
M. R. Middleton et al.
ANNALS OF ONCOLOGY (2015)
Selective Inhibition of Parallel DNA Damage Response Pathways Optimizes Radiosensitization of Glioblastoma Stem-like Cells
Shafiq U. Ahmed et al.
CANCER RESEARCH (2015)
Histone deacetylase inhibitors sensitize cancer stem cells to PARP inhibitors in triple-negative breast cancer
Yajing Liu et al.
CANCER RESEARCH (2015)
Defeating EpCAM+ liver cancer stem cells by targeting chromatin remodeling enzyme CHD4 in human hepatocellular carcinoma
Kouki Nio et al.
JOURNAL OF HEPATOLOGY (2015)
ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells
Rutger K. Balvers et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2015)
Epigenetic bivalent marking is permissive to the synergy of HDAC and PARP inhibitors on TXNIP expression in breast cancer cells
Federica Baldan et al.
ONCOLOGY REPORTS (2015)
Trapping Poly(ADP-Ribose) Polymerase
Yuqiao Shen et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2015)
Therapeutic targeting of constitutive PARP activation compromises stem cell phenotype and survival of glioblastoma-initiating cells
M. Venere et al.
CELL DEATH AND DIFFERENTIATION (2014)
PARP inhibitors and IR join forces to strike glioblastoma-initiating cells
N. Lugli et al.
CELL DEATH AND DIFFERENTIATION (2014)
Targeting DNA repair with combination veliparib (ABT-888) and temozolomide in patients with metastatic castration-resistant prostate cancer
Maha Hussain et al.
INVESTIGATIONAL NEW DRUGS (2014)
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
Junko Murai et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Antitumor and anticancer stem cell activity of a poly ADP-ribose polymerase inhibitor olaparib in breast cancer cells
Toshiro Shimo et al.
BREAST CANCER (2014)
Histone deacetylase inhibitor treatment induces 'BRCAness' and synergistic lethality with PARP inhibitor and cisplatin against human triple negative breast cancer cells
Kyungsoo Ha et al.
ONCOTARGET (2014)
DNA repair mechanisms in dividing and non-dividing cells
Teruaki Iyama et al.
DNA REPAIR (2013)
The PARP inhibitor PJ34 modifies proliferation, NIS expression and epigenetic marks in thyroid cancer cell lines
Elisa Lavarone et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2013)
Treatment with Histone Deacetylase Inhibitors Creates 'BRCAness' and Sensitizes Human Triple Negative Breast Cancer Cells to PARP Inhibitors and Cisplatin
K. N. Bhalla et al.
CANCER RESEARCH (2012)
Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
Junko Murai et al.
CANCER RESEARCH (2012)
New insights into the molecular and cellular functions of poly(ADP-ribose) and PARPs
Bryan A. Gibson et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2012)
CBX4-mediated SUMO modification regulates BMI1 recruitment at sites of DNA damage
Ismail Hassan Ismail et al.
NUCLEIC ACIDS RESEARCH (2012)
Hallmarks of Cancer: The Next Generation
Douglas Hanahan et al.
CELL (2011)
PARP-1 enhances the mismatch-dependence of 5'-directed excision in human mismatch repair in vitro
Yiyong Liu et al.
DNA REPAIR (2011)
The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
Thomas Helleday
MOLECULAR ONCOLOGY (2011)
Cancer epigenetics reaches mainstream oncology
Manuel Rodriguez-Paredes et al.
NATURE MEDICINE (2011)
Low doses of 3-aminobenzamide, a poly(ADP-ribose) polymerase inhibitor, stimulate angiogenesis by regulating expression of urokinase type plasminogen activator and matrix metalloprotease 2
Riccardo Caldini et al.
VASCULAR CELL (2011)
CD133, CD15/SSEA-1, CD34 or side populations do not resume tumor-initiating properties of long-term cultured cancer stem cells from human malignant glio-neuronal tumors
Cristina Patru et al.
BMC CANCER (2010)
Central nervous system penetration and enhancement of temozolomide activity in childhood medulloblastoma models by poly(ADP-ribose) polymerase inhibitor AG-014699
R. A. Daniel et al.
BRITISH JOURNAL OF CANCER (2010)
The properties of tumor-initiating cells from a hepatocellular carcinoma patient's primary and recurrent tumor
Xiao-Lan Xu et al.
CARCINOGENESIS (2010)
Downregulation of Homologous Recombination DNA Repair Genes by HDAC Inhibition in Prostate Cancer Is Mediated through the E2F1 Transcription Factor
Sushant K. Kachhap et al.
PLOS ONE (2010)
A chromatin localization screen reveals poly (ADP ribose)-regulated recruitment of the repressive polycomb and NuRD complexes to sites of DNA damage
Danny M. Chou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2010)
PARP inhibition: PARP1 and beyond
Michele Rouleau et al.
NATURE REVIEWS CANCER (2010)
DNA repair and cancer stem-like cells - Potential partners in glioma drug resistance?
Tor-Christian Aase Johannessen et al.
CANCER TREATMENT REVIEWS (2008)
Chromatin-modifying enzymes as therapeutic targets – Part 2
Brian R Keppler et al.
EXPERT OPINION ON THERAPEUTIC TARGETS (2008)
Human breast cancer cell lines contain stem-like cells that self-renew, give rise to phenotypically diverse progeny and survive chemotherapy
Christine M. Fillmore et al.
BREAST CANCER RESEARCH (2008)
HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination
Shanthi Adimoolam et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2007)
ABT-888, an orallyactive poly(ADP-ribose) polymerase inhibitor that potentiates DNA-damaging agents in preclinical tumor models
Cherrie K. Donawho et al.
CLINICAL CANCER RESEARCH (2007)
Mismatch repair deficiencies transforming stem cells into cancer stem cells and therapeutic implications
Minal Vaish
MOLECULAR CANCER (2007)
Glioma stem cells promote radioresistance by preferential activation of the DNA damage response
Shideng Bao et al.
NATURE (2006)
Analysis of gene expression and chemoresistance of CDI33+ cancer stem cells in glioblastoma
Gentao Liu et al.
MOLECULAR CANCER (2006)
Poly(ADP-ribose)polymerase inhibition decreases angiogenesis
Mohanraj Rajesh et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
Pharmacological inhibition of poly(ADP-ribose) polymerase inhibits angiogenesis
Mohanraj Rajesh et al.
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS (2006)
A bivalent chromatin structure marks key developmental genes in embryonic stem cells
BE Bernstein et al.
CELL (2006)
Specific killing of BRCA2-deficient tumours with inhibitors of poly(ADP-ribose) polymerase
HE Bryant et al.
NATURE (2005)
Targeting the DNA repair defect in BRCA mutant cells as a therapeutic strategy
H Farmer et al.
NATURE (2005)
Share Paper
